Benchling

Valuation $37B

About Benchling

Benchling is an IT company that provides a cloud-based software platform for biology researchers and research and development organizations.
Headquarters Benchling, San Francisco
Founded 2012-01-01
Industry Biotechnology, Life Science, Software
Last Funding Type Series F
Valuation 37
Total Funding $411.90 million dollars
IPO Status Private

Financial

Benchling may be growing as it has recently filed for a U.S. listing, which is often a sign of a company's expansion and readiness to access more capital. Additionally, the partnership with Zealand Pharma indicates an expansion of its business relationships and potential increase in its user base. The move towards an IPO, as detailed in the overview article, suggests that Benchling is preparing for a significant financial milestone that could support further growth.

Benchling is engaged in developing tools for molecular sequence design, enabling automatic generation of molecular constructs through user interface presentations. They are also advancing methods for searching chemical structures, facilitating the identification of molecules and compounds. Additionally, Benchling is enhancing molecular databases by updating target molecule components and visualizing synthetically-modified nucleotide sequences. These efforts are complemented by a machine learning research platform that optimizes life sciences experiments, underscoring their focus on innovative solutions for biology research.

Funding Rounds 9
Number of Lead Investors 8
Total Funding Amount  $411.90 million dollars
Number of Investors 23

Related Angels

Christopher Golda
View profile
Adam Draper
View profile
Kevin Mahaffey
View profile
Felix Shpilman
View profile
Ashton Kutcher
View profile